1
|
Deng Y, Chen F, Li Y, Qian K, Wang R, Zhou XH. A powerful test for the maximum treatment effect in thorough QT/QTc studies. Stat Med 2021; 40:1947-1959. [PMID: 33463746 DOI: 10.1002/sim.8881] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2020] [Revised: 10/21/2020] [Accepted: 01/01/2021] [Indexed: 11/08/2022]
Abstract
Parallel-group thorough QT/QTc studies focus on the change of QT/QTc values at several time-matched points from a pretreatment day (baseline) to a posttreatment day for different groups of treatment. The International Council for Harmonisation E14 stresses that QTc prolongation beyond a threshold represents high cardiac risk and calls for a test on the largest time-matched treatment effect (QTc prolongation). QT/QTc analysis usually assumes a jointly multivariate normal (MVN) distribution of pretreatment and posttreatment QT/QTc values, with a blocked compound symmetry covariance matrix. Existing methods use an analysis of covariance (ANCOVA) model including day-averaged baseline as a covariate to deal with the MVN model. However, the ANCOVA model tends to underestimate the variation of the estimator for treatment effects, resulting in the inflation of empirical type I error rate when testing whether the largest QTc prolongation is beyond a threshold. In this article, we propose two new methods to estimate the time-matched treatment effects under the MVN model, including maximum likelihood estimation and ordinary-least-square-based two-stage estimation. These two methods take advantage of the covariance structure and are asymptotically efficient. Based on these estimators, powerful tests for QT/QTc prolongation are constructed. Simulation shows that the proposed estimators have smaller mean square error, and the tests can control the type I error rate with high power. The proposed methods are applied on testing the carryover effect of diltiazem to inhibit dofetilide in a randomized phase 1 trial.
Collapse
Affiliation(s)
- Yuhao Deng
- School of Mathematical Sciences, Peking University, Beijing, China
| | - Fangyi Chen
- Department of Statistics, Columbia University, New York City, USA
| | - Yang Li
- Academy for Advanced Interdisciplinary Studies, Peking University, Beijing, China
| | - Kaihuan Qian
- Department of Biostatistics, School of Public Health, Peking University, Beijing, China
| | - Rui Wang
- Department of Biostatistics, School of Public Health, Peking University, Beijing, China
| | - Xiao-Hua Zhou
- Department of Biostatistics, School of Public Health, Peking University, Beijing, China.,Beijing International Center for Mathematical Research, Peking University, Beijing, China
| |
Collapse
|
2
|
Becker A, Martin EC, Mitchell DY, Grenningloh R, Bender AT, Laurent J, Mackenzie H, Johne A. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers. Clin Transl Sci 2019; 13:325-336. [PMID: 31654487 PMCID: PMC7070898 DOI: 10.1111/cts.12713] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Accepted: 09/18/2019] [Indexed: 01/07/2023] Open
Abstract
Bruton's tyrosine kinase (BTK) is a key regulator of B cell receptor and Fc receptor signaling, and a rational therapeutic target for autoimmune diseases. This first‐in‐human phase I, double‐blind, placebo‐controlled trial investigated the safety, tolerability, pharmacokinetics (PK), target occupancy, and effects on QT interval of evobrutinib, a highly selective, oral inhibitor of BTK, in healthy subjects. This dose escalation trial consisted of two parts. Part 1 included 48 subjects in 6 ascending dose cohorts (25, 50, 100, 200, 350, and 500 mg) randomized to a single dose of evobrutinib or placebo. Part 2 included 36 subjects in 3 ascending dose cohorts (25, 75, and 200 mg/day) randomized to evobrutinib or placebo once daily for 14 days. Safety and tolerability, as well as PK and target occupancy (total and free BTK in peripheral blood mononuclear cells), were assessed following single and multiple dosing. PK parameters were determined by noncompartmental methods. QT interval was obtained from 12‐lead electrocardiogram recordings and corrected for heart rate by Fridericia's method (QTcF). Treatment‐emergent adverse events (TEAEs) were mostly mild, occurring in 25% of subjects after single dosing, and 48.1% after multiple dosing. There was no apparent dose relationship regarding frequency or type of TEAE among evobrutinib‐treated subjects. Absorption was rapid (time to reach maximum plasma concentration (Tmax) ~ 0.5 hour), half‐life short (~ 2 hours), and PK dose‐proportional, with no accumulation or time dependency on repeat dosing. BTK occupancy was dose‐dependent, reaching maximum occupancy of > 90% within ~ 4 hours after single doses ≥ 200 mg; the effect was long‐lasting (> 50% occupancy at 96 hours with ≥ 100 mg). After multiple dosing, full BTK occupancy was achieved with 25 mg, indicating slow turnover of BTK protein in vivo. Concentration‐QTcF analyses did not show any impact of evobrutinib concentration on corrected QT (QTc). In summary, evobrutinib was well‐tolerated, showed linear and time‐independent PK, induced long‐lasting BTK inhibition, and was associated with no prolongation of QT/QTc interval in healthy subjects. Evobrutinib is, therefore, suitable for investigation in autoimmune diseases.
Collapse
Affiliation(s)
| | - Emily C Martin
- EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA
| | | | - Roland Grenningloh
- EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA
| | - Andrew T Bender
- EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA
| | | | - Harald Mackenzie
- EMD Serono Research & Development Institute, Inc., Billerica, Massachusetts, USA
| | | |
Collapse
|
3
|
Wiśniowska B, Tylutki Z, Polak S. Thorough QT (TQT) studies: concordance with torsadogenesis and an evolving cardiac safety testing paradigm. Drug Discov Today 2017; 22:1460-1465. [PMID: 28511997 DOI: 10.1016/j.drudis.2017.04.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2016] [Revised: 03/30/2017] [Accepted: 04/26/2017] [Indexed: 01/08/2023]
Abstract
Since 2005, when the International Conference on Harmonisation (ICH) E14 guideline was adopted, no drug has been withdrawn because of QTc prolongation or torsade de pointes arrhythmia. There are, however, costs associated with this success. In addition to the time and money invested, thorough QT (TQT) studies have limited the efficiency of the drug development pipeline. In this paper, we discuss the relevance of TQT trials as a tool for proarrhythmic risk prediction as a part of the debate regarding their usefulness.
Collapse
Affiliation(s)
- Barbara Wiśniowska
- Pharmacoepidemiology and Pharmacoeconomics Unit, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Str., 30-688 Krakow, Poland.
| | - Zofia Tylutki
- Pharmacoepidemiology and Pharmacoeconomics Unit, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Str., 30-688 Krakow, Poland
| | - Sebastian Polak
- Pharmacoepidemiology and Pharmacoeconomics Unit, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, Str., 30-688 Krakow, Poland; Simcyp (part of Certara), Sheffield S2 4SU, UK
| |
Collapse
|
4
|
Vo LC, Snyder C, McCracken C, McDougle CJ, McCracken JT, Aman MG, Tierney E, Arnold LE, Levi D, Kelleman M, Carroll D, Morrissey J, Vitiello B, Scahill L. No Apparent Cardiac Conduction Effects of Acute Treatment with Risperidone in Children with Autism Spectrum Disorder. J Child Adolesc Psychopharmacol 2016; 26:900-908. [PMID: 27726426 PMCID: PMC5178011 DOI: 10.1089/cap.2016.0090] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
OBJECTIVES Risperidone is approved for the treatment of serious behavioral problems in children with autism spectrum disorder (ASD). This study examined the effects of risperidone on cardiac conduction in children with ASD. METHODS Data were collected from an 8-week, five-site trial conducted by the Research Units on Pediatric Psychopharmacology Autism Network. Children (age 5-17 years) were randomly assigned to risperidone (n = 49) or placebo (n = 52) under double-blind conditions. Risperidone was superior to placebo in reducing serious behavioral problems. A standard 12-lead, electrocardiogram (ECG) was obtained in most subjects at screening and week 8. A pediatric electrophysiologist blind to treatment assignment reviewed all available ECGs for readability, abnormalities, and cardiac conduction parameters, including QTc. The electrophysiologist measurements were compared to machine readings. A second blinded electrophysiologist examined all available ECGs for abnormalities and a 20% random sample for QTc. RESULTS Of the 101 randomized subjects in the trial, complete pretreatment and week 8 data were available on 65 subjects (placebo n = 30; risperidone n = 35). The electrophysiologist did not identify any cardiac conduction adverse effects of risperidone and there was no difference in mean change on the QTc compared to placebo. The Bland-Altman plot showed a systematic bias in QTc measurements by the electrophysiologist and machine. Machine readings produced higher values than the electrophysiologist for shorter QTc intervals and machine scoring was lower than electrophysiologist readings for longer QTc values (p = 0.001). Two electrophysiologists had overall percent agreements of 82.9% (95% CI: 76.3 to 89.6) on qualitative assessment and 88.6% (95% CI: 79.3 to 98.0) on QTc interval. CONCLUSION Using conventional doses during acute treatment in children with ASD and serious behavioral problems, there was no difference in the mean change in QTc between risperidone and placebo. Compared to the electrophysiologist, the machine readings may miss elevated QTc measurements.
Collapse
Affiliation(s)
- Lan Chi Vo
- Department of Psychiatry, Emory University School of Medicine, Atlanta, Georgia
| | - Christopher Snyder
- Division of Pediatric Cardiology, University Hospitals Rainbow Babies and Children's Hospital, Cleveland, Ohio
| | - Courtney McCracken
- Children's Hospital of Atlanta & Emory University School of Medicine, Atlanta, Georgia
| | - Christopher J. McDougle
- Harvard Medical School, Massachusetts General Hospital, Lurie Center for Autism, Boston, Massachusetts
| | - James T. McCracken
- Division of Child Psychiatry, University of California at Los Angeles, Los Angeles, California
| | | | | | | | - Daniel Levi
- Mattel Children's Hospital, University of California at Los Angeles, Los Angeles, California
| | - Michael Kelleman
- Children's Hospital of Atlanta & Emory University School of Medicine, Atlanta, Georgia
| | - Deirdre Carroll
- Yale Child Study Center, Yale University School of Medicine, New Haven, Connecticut
| | - John Morrissey
- Mattel Children's Hospital, University of California at Los Angeles, Los Angeles, California
| | | | - Lawrence Scahill
- Marcus Autism Center, Emory University School of Medicine, Atlanta, Georgia
| |
Collapse
|
5
|
Gelotte CK, Zimmerman BA. Pharmacokinetics, safety, and cardiovascular tolerability of phenylephrine HCl 10, 20, and 30 mg after a single oral administration in healthy volunteers. Clin Drug Investig 2016; 35:547-58. [PMID: 26267590 PMCID: PMC4559581 DOI: 10.1007/s40261-015-0311-9] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND AND OBJECTIVES Phenylephrine HCl 10 mg has been used as a nasal decongestant for over 50 years, yet only limited pharmacokinetic and metabolic data are available. The purpose of this study was to evaluate single-dose pharmacokinetics and safety of phenylephrine HCl 10, 20, and 30 mg and to assess cardiovascular tolerability compared with baseline and placebo in healthy volunteers. METHODS Twenty-eight adults were enrolled in this randomized, double-blind, placebo-controlled, single-dose, four-treatment crossover study. Subjects remained housed for 6 days to permit time-matched, serial measurements of pulse, blood pressure, and electrocardiograms (ECGs) for baseline and complete treatments on consecutive days. After fasting overnight, subjects were dosed with oral phenylephrine HCl 10, 20, or 30 mg or placebo. Pharmacokinetic blood samples were collected over 7 h, whereas pulse, blood pressure, and ECGs were measured over 12 h. Urine was collected over each 24-h period to quantify phenylephrine and metabolites. RESULTS After oral administration, phenylephrine was rapidly absorbed with median times to maximum plasma concentrations (t max) from 0.33 to 0.5 h. For phenylephrine HCl 10, 20, and 30 mg, the mean (standard deviation) maximum concentration (C max) was 1354 (954), 2959 (2122), and 4492 (1978) pg/mL, and total systemic exposure [area under the plasma concentration-time curve from time zero to infinity (AUC∞)] was 955.8 (278.5), 2346 (983.8), and 3900 (1764) pg·h/mL, respectively. Both parameters increased disproportionally with increasing dose, as β >1 in the power model. Negligible amounts of phenylephrine and phenylephrine glucuronide were excreted in urine. With increasing dose, percentages by dose of phenylephrine sulfate decreased, whereas percentages of 3-hydroxymandelic acid increased. Eight subjects reported nine mild adverse events; one (somnolence) was deemed to be treatment related. Means of time-matched differences in pulse and blood pressure from baseline showed similar fluctuations over 12 h among phenylephrine HCl doses and placebo, although small differences in systolic pressure were observed during the initial 2 h. No apparent dose-related effects were observed for Fridericia-corrected QT interval (QTcF) values, and individual changes from time-matched baseline (DQTcF). CONCLUSIONS Maximum and total systemic exposures following singe doses of phenylephrine HCl 10, 20, and 30 mg increased disproportionally with increasing dose. Safety and cardiovascular tolerability were comparable among doses and placebo.
Collapse
Affiliation(s)
- Cathy K Gelotte
- McNeil Consumer Healthcare, A Division of Johnson & Johnson Consumer, Inc., 7050 Camp Hill Road, Fort Washington, PA, 19034, USA,
| | | |
Collapse
|
6
|
Hoffman D. Circadian Variation and Baseline Definition in Parallel-Group Thorough QT Studies. Ther Innov Regul Sci 2014; 48:272-286. [PMID: 30227508 DOI: 10.1177/2168479013503168] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
For thorough QT (TQT) studies employing a parallel-group design, there has been a clear regulatory preference for the use of time-matched, rather than time-averaged, baseline values to account for circadian variation when estimating the magnitude of the drug effect on the QT interval. In this paper, both historical data from parallel-group TQT studies and simulated data from assumed circadian models are utilized to comprehensively assess the performance characteristics of 3 repeated-measures analysis of covariance models. The results indicate that each analysis model performs adequately in the absence of an observed time-matched baseline imbalance between the treatment groups. However, the analysis model with time-matched baseline as a covariate performs poorly under the setting of an observed time-matched baseline imbalance between the treatment groups. The analysis model with time-averaged baseline as a covariate and the analysis model with both time-matched and time-averaged baselines as covariates provide unbiased estimates of the treatment difference and properly control the type I error rate, regardless of an observed time-matched baseline imbalance or within-patient variation in circadian parameters.
Collapse
Affiliation(s)
- David Hoffman
- 1 Early Development Biostatistics, Sanofi, Bridgewater, NJ, USA
| |
Collapse
|
7
|
Mason JW. Timing of pre-dose baseline electrocardiograms in clinical trials: increased sampling over a prolonged baseline period worsens variance of QTc. J Electrocardiol 2014; 47:716-20. [PMID: 25060126 DOI: 10.1016/j.jelectrocard.2014.07.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND AND PURPOSE The US Food and Drug Administration (US FDA) currently recommends recording of electrocardiograms (ECGs) prior to drug administration in thorough QT studies over an hour or more time to improve reliability of baseline ECG values. However, the baseline period is usually in the morning during a period of intense trial activity and rapid circadian change in QTc. The purpose of this study was to determine if the practice of recording an extended baseline does, in fact, decrease QTc variance at baseline. METHODS ECG data from three thorough QT studies (TQTS) in which three ECGs (commonly referred to as triplicates) were recorded at each of three pre-specified time points during the 60 to 90 minutes before drug administration were analyzed by determining the intra-subject and inter-subject standard deviation (SD) of QTcF (Fridericia-correct QT) for each of the three pre-drug time points and for the three time points combined. RESULTS QTcF was relatively normally distributed in each study. Intra-subject variability of QTcF was greater for the combined triplicate recordings than for the individual triplicates at baseline treatment time points in 39 of 42 cases (93%). This was the case in 48% of the comparisons in the inter-subject analysis. CONCLUSIONS The practice of recording three sets of triplicate ECGs over an hour or more before drug administration in a TQTS increases variability of baseline QTcF consistently in cross-over designed trials, and in roughly half of parallel comparisons. Higher variability suggests that the three-triplicate approach does not provide a more reliable baseline value. Less variability of QTcF can be obtained by simply recording one triplicate prior to drug administration. This principal may apply to other ECG and other physiological variables that have a monotonic circadian trend or that may be affected by intense trial activity during the pre-drug hour.
Collapse
Affiliation(s)
- Jay W Mason
- University of Utah, Salt Lake City, UT, USA.
| |
Collapse
|
8
|
Abstract
Whether or not QTc interval should be routinely monitored in patients receiving antipsychotics is a controversial issue, given logistic and fiscal dilemmas. There is a link between antipsychotic medications and prolongation of QTc interval, which is associated with an increased risk of torsade de pointes (TdP). Our goal is to provide clinically practical guidelines for monitoring QTc intervals in patients being treated with antipsychotics. We provide an overview of the pathophysiology of the QT interval, its relationship to TdP, and a discussion of the QT prolonging effects of antipsychotics. A literature search for articles relevant to the QTc prolonging effects of antipsychotics and TdP was conducted utilizing the databases PubMed and Embase with various combinations of search words. The overall risk of TdP and sudden death associated with antipsychotics has been observed to be low. Medications, genetics, gender, cardiovascular status, pathological conditions, and electrolyte disturbances have been found to be related to prolongation of the QTc interval. We conclude that, while electrocardiogram (ECG) monitoring is useful when administering antipsychotic medications in the presence of co-existing risk factors, it is not mandatory to perform ECG monitoring as a prerequisite in the absence of cardiac risk factors. An ECG should be performed if the initial evaluation suggests increased cardiac risk or if the antipsychotic to be prescribed has been established to have an increased risk of TdP and sudden death.
Collapse
|
9
|
Navarrete EG, Liang P, Lan F, Sanchez-Freire V, Simmons C, Gong T, Sharma A, Burridge PW, Patlolla B, Lee AS, Wu H, Beygui RE, Wu SM, Robbins RC, Bers DM, Wu JC. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 2013; 128:S3-13. [PMID: 24030418 DOI: 10.1161/circulationaha.112.000570] [Citation(s) in RCA: 222] [Impact Index Per Article: 20.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
BACKGROUND Drug-induced arrhythmia is one of the most common causes of drug development failure and withdrawal from market. This study tested whether human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) combined with a low-impedance microelectrode array (MEA) system could improve on industry-standard preclinical cardiotoxicity screening methods, identify the effects of well-characterized drugs, and elucidate underlying risk factors for drug-induced arrhythmia. hiPSC-CMs may be advantageous over immortalized cell lines because they possess similar functional characteristics as primary human cardiomyocytes and can be generated in unlimited quantities. METHODS AND RESULTS Pharmacological responses of beating embryoid bodies exposed to a comprehensive panel of drugs at 65 to 95 days postinduction were determined. Responses of hiPSC-CMs to drugs were qualitatively and quantitatively consistent with the reported drug effects in literature. Torsadogenic hERG blockers, such as sotalol and quinidine, produced statistically and physiologically significant effects, consistent with patch-clamp studies, on human embryonic stem cell-derived cardiomyocytes hESC-CMs. False-negative and false-positive hERG blockers were identified accurately. Consistent with published studies using animal models, early afterdepolarizations and ectopic beats were observed in 33% and 40% of embryoid bodies treated with sotalol and quinidine, respectively, compared with negligible early afterdepolarizations and ectopic beats in untreated controls. CONCLUSIONS We found that drug-induced arrhythmias can be recapitulated in hiPSC-CMs and documented with low impedance MEA. Our data indicate that the MEA/hiPSC-CM assay is a sensitive, robust, and efficient platform for testing drug effectiveness and for arrhythmia screening. This system may hold great potential for reducing drug development costs and may provide significant advantages over current industry standard assays that use immortalized cell lines or animal models.
Collapse
Affiliation(s)
- Enrique G Navarrete
- Department of Medicine, Division of Cardiology, Stanford University School of Medicine, Stanford, CA (E.G.N., P.L., F.L., V.S.-F., T.G., A.S., P.W.B., A.S.L., H.W., S.M.W., J.C.W.); Institute for Stem Cell Biology and Regenerative Medicine, Stanford, CA (E.G.N., P.L., F.L., V.S.-F., T.G., A.S., P.W.B., A.S.L., H.W., S.M.W.); Stanford Cardiovascular Institute, Stanford, CA (E.G.N., P.L., F.L., V.S.-F., C.S., T.G., P.W.B., B.P., A.S.L., H.W., R.E.B., S.M.W., R.C.R., J.C.W.); Department of Radiology, Stanford, CA (E.G.N., P.L., F.L., V.S.-F., T.G., P.W.B., A.S.L., H.W., J.C.W.); School of Mechanical Engineering, Stanford, CA (C.S.); Department of Cardiothoracic Surgery, Stanford, CA (B.P., R.E.B., R.C.R.); Department of Pharmacology, University of California, Davis, CA (D.M.B.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
10
|
Sugiyama A, Hashimoto H, Nakamura Y, Fujita T, Kumagai Y. QT/QTc study conducted in Japanese adult healthy subjects: A novel xanthine oxidase inhibitor topiroxostat was not associated with QT prolongation. J Clin Pharmacol 2013; 54:446-52. [DOI: 10.1002/jcph.226] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2013] [Accepted: 11/04/2013] [Indexed: 01/08/2023]
Affiliation(s)
- Atsushi Sugiyama
- Department of Pharmacology; Faculty of Medicine; Toho University; Omori-Nishi, Ota-ku Tokyo Japan
- Yamanashi Research Center of Clinical Pharmacology; Iwasa-cho; Fuefuki Yamanashi Japan
| | - Hiroya Hashimoto
- Project Development Department; Sanwa Kagaku Kenkyusho Co., Ltd.; Higashisotobori-cho, Higashi-ku Nagoya Aichi Japan
| | - Yuji Nakamura
- Department of Pharmacology; Faculty of Medicine; Toho University; Omori-Nishi, Ota-ku Tokyo Japan
| | - Tomoe Fujita
- Clinical Trial Center; Kitasato University East Hospital; Asamizodai, Minami-ku Sagamihara Kanagawa Japan
| | - Yuji Kumagai
- Clinical Trial Center; Kitasato University East Hospital; Asamizodai, Minami-ku Sagamihara Kanagawa Japan
| |
Collapse
|
11
|
Suico JG, Friedrich S, Krueger KA, Zhang W. Evacetrapib at a Supratherapeutic Steady State Concentration Does Not Prolong QT in a Thorough QT/QTc Study in Healthy Participants. J Cardiovasc Pharmacol Ther 2013; 19:283-9. [DOI: 10.1177/1074248413510784] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Purpose: To evaluate whether evacetrapib prolongs QT intervals in healthy participants. Methods: This was a single-center, randomized, active and placebo-controlled, 3-period, 6-sequence, and crossover study. Participants were randomized to 1 of 6 treatment sequences in which they received 1 of 3 treatments: evacetrapib 1200 mg daily for 10 days (supratherapeutic dose), moxifloxacin 400 mg for 1 day (positive control), or placebo for 10 days in each of the 3 separate treatment periods. Electrocardiographic parameters were recorded at time points specified in the protocol. The primary end point was the comparison of evacetrapib effect on the population-corrected QT interval (QTcP) to that of placebo at 7 time points following dosing on day 10. An upper limit of the 2-sided 90% confidence interval (CI) <10 milliseconds confirmed the absence of significant effect. Pharmacokinetic parameters were also calculated. Results: Subjects were predominantly male (73.2%) with a mean age of 43.1 years and a mean body mass index of 25.9 kg/m2. For the primary analysis, the upper bound of the 2-sided 90% CI for the mean difference between evacetrapib and placebo was <10 milliseconds at all time points on day 10. Following administration of moxifloxacin, the QTcP increased by ≥5 milliseconds at all time points (2, 3, and 4 hours postdose). Maximum plasma concentrations of evacetrapib occurred at a median time of approximately 2 hours, and the mean apparent elimination half-life was approximately 41 hours. The area under the curve and Cmax achieved in this study were both ∼5-fold the values that are expected with the dose level being studied in a phase 3 cardiovascular outcome study. A 1200-mg supratherapeutic dose of evacetrapib was considered to be well tolerated after 10 days of daily dosing in healthy participants. Conclusions: Evacetrapib is not associated with QT interval prolongation, even at supratherapeutic doses.
Collapse
Affiliation(s)
| | | | | | - Wei Zhang
- Eli Lilly and Company, Indianapolis, IN, USA
| |
Collapse
|
12
|
Russell T, Riley SP, Cook JA, Lalonde RL. A Perspective on the Use of Concentration-QT Modeling in Drug Development. J Clin Pharmacol 2013; 48:9-12. [DOI: 10.1177/0091270007311115] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
13
|
Hutmacher MM, Chapel S, Agin MA, Fleishaker JC, Lalonde RL. Performance Characteristics for Some Typical QT Study Designs Under the ICH E-14 Guidance. J Clin Pharmacol 2013; 48:215-24. [DOI: 10.1177/0091270007311921] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
14
|
Holzgrefe HH, Ferber G, Morrison R, Meyer O, Greiter-Wilke A, Singer T. Characterization of the Human QT Interval: Novel Distribution-Based Assessment of the Repolarization Effects of Moxifloxacin. J Clin Pharmacol 2013; 52:1222-39. [DOI: 10.1177/0091270011409234] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
15
|
Natekar M, Hingorani P, Gupta P, Karnad DR, Kothari S, de Vries M, Zumbrunnen T, Narula D. Effect of number of replicate electrocardiograms recorded at each time point in a thorough QT study on sample size and study cost. J Clin Pharmacol 2010; 51:908-14. [PMID: 20852005 DOI: 10.1177/0091270010376962] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
In a "thorough QT/QTc" (TQT) study, several replicate electrocardiograms (ECGs) are recorded at each time point to reduce within-subject variability. This decreases the sample size but increases the cost of ECG analysis. To determine the most cost-effective number of ECG replicates, the authors retrospectively analyzed data from the placebo and moxifloxacin arms of a TQT study with crossover design. Six replicate ECGs were recorded at 7 time points on day -1 (baseline day), day 1, and day 3 in 124 normal healthy volunteers who were randomized to receive moxifloxacin or placebo on day 1 and the other treatment on day 3. QT interval was corrected for heart rate by the Fridericia (QTcF) and individual subject-specific (QTcI) formulas. Within-subject and between-subject standard deviations for QTcF obtained by repeated-measures analysis of covariance were 9.5 and 13.3 milliseconds with 1 replicate; 7.8 and 12.7 milliseconds with 2 replicates; 7.3 and 12.3 milliseconds with 3 replicates; 6.9 and 12.2 milliseconds with 4 replicates; 6.8 and 11.9 milliseconds with 5 replicates; and 6.6 and 11.8 milliseconds with 6 replicates. Within- and between-subject variance with QTcI also declined with increasing replicates. Sample size benefit based on these estimates was negligible beyond 4 replicates. The study cost was least with 3 or 4 replicates, depending on per-ECG and per-subject costs.
Collapse
Affiliation(s)
- Mili Natekar
- Quintiles Cardiac Safety Services, Research Section, 502A, Leela Business Park, M.V Road, Andheri East, Mumbai, India
| | | | | | | | | | | | | | | |
Collapse
|
16
|
Chen J, Zhao X. A Bayesian measurement error approach to QT interval correction and prolongation. J Biopharm Stat 2010; 20:523-42. [PMID: 20358434 DOI: 10.1080/10543400903581960] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
Assessment of QT interval prolongation is an integral part of clinical studies in drug development because a prolonged QT interval can cause sudden cardiac death. Traditionally a linear or non-linear regression method is applied to estimate subject- or group-specific heart rate corrected QT intervals (QTc) on which comparisons are based among treatment groups. These regression models rely on a fundamental assumption that the predictor variable (RR interval) is measured without error. However, the fact is that both QT and RR intervals measured in electrocardiogram (ECG) are subject to not only measurement error, but also fluctuation that is caused by physiological and biological factors. Hence the assumption in the regression models is most likely violated. In this paper we propose a Bayesian hierarchical measurement error model to evaluate QTc interval and prolongation. The proposed approach is illustrated using a real data set. Simulation studies show that our proposed Bayesian measurement error approach outperforms the current most commonly used frequentist methods.
Collapse
Affiliation(s)
- Jie Chen
- Abbott Laboratories, Abbott Park, Illinois, USA.
| | | |
Collapse
|
17
|
Meng Z, Kringle R, Chen X, Zhao PL. Sample size calculation for thorough QT/QTc study considering various factors related to multiple time points. J Biopharm Stat 2010; 20:587-603. [PMID: 20358436 DOI: 10.1080/10543400903582000] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
The sample size requirement in a thorough QT/QTc study is discussed under a balanced parallel or crossover study design. First, we explore the impacts of various factors on the study power, including the mean effect profile across time and correlation among time points. Then we estimate the variability parameters needed based on multiple historical studies. Different baseline usage is illustrated to have a significant impact on the analysis variability in the parallel studies. Finally, the sample size calculations and recommendations are given for demonstrating a "negative" drug effect and the study assay sensitivity, respectively.
Collapse
Affiliation(s)
- Zhaoling Meng
- Biostatistics and Programming, Sanofi-Aventis, Bridgewater, New Jersey, USA.
| | | | | | | |
Collapse
|
18
|
Meng Z, Quan H, Fan L, Kringle R, Sun G. Use of the Average Baseline Versus the Time-Matched Baseline in Parallel Group Thorough QT/QTc Studies. J Biopharm Stat 2010; 20:665-82. [DOI: 10.1080/10543400903582067] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Affiliation(s)
- Zhaoling Meng
- a Biostatistics and Programming, Sanofi-Aventis , Bridgewater, New Jersey, USA
| | - Hui Quan
- a Biostatistics and Programming, Sanofi-Aventis , Bridgewater, New Jersey, USA
| | - Li Fan
- a Biostatistics and Programming, Sanofi-Aventis , Bridgewater, New Jersey, USA
| | - Robert Kringle
- a Biostatistics and Programming, Sanofi-Aventis , Bridgewater, New Jersey, USA
| | - Gordon Sun
- a Biostatistics and Programming, Sanofi-Aventis , Bridgewater, New Jersey, USA
| |
Collapse
|
19
|
Anand SP, Ghosh SK. A flexible class of models for data arising from a 'thorough QT/QTc study'. Pharm Stat 2010; 10:122-7. [PMID: 20306546 DOI: 10.1002/pst.420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The standard methods for analyzing data arising from a 'thorough QT/QTc study' are based on multivariate normal models with common variance structure for both drug and placebo. Such modeling assumptions may be violated and when the sample sizes are small, the statistical inference can be sensitive to such stringent assumptions. This article proposes a flexible class of parametric models to address the above-mentioned limitations of the currently used models. A Bayesian methodology is used for data analysis and models are compared using the deviance information criteria. Superior performance of the proposed models over the current models is illustrated through a real dataset obtained from a GlaxoSmithKline (GSK) conducted 'thorough QT/QTc study'.
Collapse
Affiliation(s)
- Suraj P Anand
- Department of Statistics, NC State University, Raleigh, NC, USA
| | | |
Collapse
|
20
|
Graff C, Matz J, Christensen EB, Andersen MP, Kanters JK, Toft E, Pehrson S, Hardahl TB, Nielsen J, Struijk JJ. Quantitative analysis of T-wave morphology increases confidence in drug-induced cardiac repolarization abnormalities: evidence from the investigational IKr inhibitor Lu 35-138. J Clin Pharmacol 2010; 49:1331-42. [PMID: 19843657 DOI: 10.1177/0091270009344853] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
This study investigates repolarization changes induced by a new candidate drug to determine whether a composite electrocardiographic (ECG) measure of T-wave morphology could be used as a reliable marker to support the evidence of abnormal repolarization, which is indicated by QT interval prolongation. Seventy-nine healthy subjects were included in this parallel study. After a baseline day during which no drug was given, 40 subjects received an I(Kr)-blocking antipsychotic compound (Lu 35-138) on 7 consecutive days while 39 subjects received placebo. Resting ECGs were recorded and used to determine a combined measure of repolarization morphology (morphology combination score [MCS]), based on asymmetry, flatness, and notching. Replicate measurements were used to determine reliable change and study power for both measures. Lu 35-138 increased the QTc interval with corresponding changes in T-wave morphology as determined by MCS. For subjects taking Lu 35-138, T-wave morphology was a more reliable indicator of I(Kr) inhibition than QTcF (chi(2) = 20.3, P = .001). At 80% study power for identifying a 5-millisecond placebo-adjusted change from baseline for QTcF, the corresponding study power for MCS was 93%. As a covariate to the assessment of QT interval liability, MCS offered important additive information to the effect of Lu 35-138 on cardiac repolarization.
Collapse
Affiliation(s)
- Claus Graff
- Department of Health Science and Technology, Center for Sensory Motor Interaction, Aalborg University, Aalborg, Denmark.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
21
|
Darpo B. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance. Br J Pharmacol 2010; 159:49-57. [PMID: 19922536 PMCID: PMC2823351 DOI: 10.1111/j.1476-5381.2009.00487.x] [Citation(s) in RCA: 110] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2009] [Revised: 08/11/2009] [Accepted: 08/20/2009] [Indexed: 01/08/2023] Open
Abstract
The ICH E14 guidance on how to clinically assess a new drug's liability to prolong the QT interval was adopted in May 2005. A centre-piece of the guidance was the establishment of one single trial, the 'thorough QT/QTc study', intended to confidently identify drugs that may cause QT prolongation. Initially perceived as a great challenge, this study has rapidly become a standard component of all clinical development programs for new molecular entities. The study is normally conducted in healthy volunteers, includes both a positive and a negative (placebo) control and is stringently powered to exclude an effect on the QTc interval exceeding 10 ms. The E14 guidance was intentionally not very prescriptive and allowed sponsors and service providers to explore new methodologies. This has allowed for a rapid development of new methods during the first years after the guidance's implementation, such as computer-assisted algorithms for QT measurements. Regulators have worked in close collaboration with pharmaceutical industry to set standards for the design and conduct of the 'thorough QT/QTc study', which therefore has evolved as a key component of cardiac safety assessment of new drugs. This paper summarizes the requirements on the 'thorough QT/QTc study' with emphasis on the standard that has evolved based on interactions between regulators and sponsors and the experience from a large number of completed studies.
Collapse
Affiliation(s)
- Borje Darpo
- Department of Clinical Science and Education, Section of Cardiology, Karolinska Institute, South Hospital, Stockholm, Sweden.
| |
Collapse
|
22
|
Salvi V, Karnad DR, Panicker GK, Kothari S. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development. Br J Pharmacol 2009; 159:34-48. [PMID: 19775279 DOI: 10.1111/j.1476-5381.2009.00427.x] [Citation(s) in RCA: 80] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Following reports of death from cardiac arrhythmias with drugs like terfenadine and cisapride, the International Conference for Harmonization formulated a guidance (E14) document. This specifies that all new drugs must undergo a 'thorough QT/QTc' (TQT) study to detect drug-induced QT prolongation, a surrogate marker of ventricular tachycardia, especially torsades de pointes (TdPs). With better understanding of data from several completed TQT studies, regulatory requirements have undergone some changes since the E14 guidance was implemented in October 2005. This article reviews the implications of the E14 guidance and the changes in its interpretation including choice of baseline QT, demonstration of assay sensitivity, statistical analysis of the effect of new drug and positive control, and PK-PD modelling. Some issues like use of automated QT measurements remain unresolved. Pharmaceutical companies too are modifying Phase 1 studies to detect QTc liability early in order to save time and resources. After the E14 guidance, development of several drugs that prolong QTc by >5 ms is being abandoned by sponsors. However, all drugs that prolong the QT interval do not increase risk of TdP. Researchers in regulatory agencies, academia and industry are working to find better biomarkers of drug-induced TdP which could prevent many useful drugs from being prematurely abandoned. Drug-induced TdP is a rare occurrence. With fewer drugs that prolong QT interval reaching the licensing stage, knowing which of these drugs are torsadogenic is proving to be elusive. Thus, paradoxically, the effectiveness of the E14 guidance itself has made prospective validation of new biomarkers difficult.
Collapse
Affiliation(s)
- Vaibhav Salvi
- Quintiles ECG Services, Andheri (East), Mumbai, India.
| | | | | | | |
Collapse
|
23
|
Hulhoven R, Rosillon D, Bridson WE, Meeus MA, Salas E, Stockis A. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study. Clin Ther 2009; 30:260-70. [PMID: 18343264 DOI: 10.1016/j.clinthera.2008.02.002] [Citation(s) in RCA: 37] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/20/2007] [Indexed: 11/18/2022]
Abstract
BACKGROUND Nonantiarrhythmic drugs may have the potential to prolong the QT interval, leading to potentially fatal ventricular tachycardias, including torsades de pointes. OBJECTIVE This study evaluated the potential of the newer-generation, multiple-action antiepileptic drug levetiracetam, which binds to the synaptic vesicle protein SV2A, to affect cardiac repolarization, as detected by prolongation of the QT/corrected QT (QTc) interval. METHODS This was a single-dose, randomized, placebo- and active-controlled, 4-way crossover study in healthy subjects. Subjects were randomly allocated to 1 of 4 different administration sequences. Each sequence included 3 double-blind treatments (levetirace-tam 1000 mg, levetiracetam 5000 mg, and placebo) and 1 open-label treatment (moxifloxacin 400 mg). Triplicate electrocardiograms (ECGs) were obtained at baseline and at various time points over 24 hours after each treatment using continuous Holter monitoring. ECGs were read centrally in a blinded manner. Blood samples for the determination of plasma concentrations of levetiracetam and moxifloxacin were collected before dosing and at 0.5, 1, 1.5, 2, 4, 6, 12, and 24 hours after dosing, within 5 minutes after the ECG recordings. The QT interval was corrected for heart rate using a sex- and study-specific correction (QTc(ss)) as the primary outcome measure and Fridericia's correction (QTc(F))as a secondary outcome measure. The primary analysis was performed on the time-matched, baseline-subtracted QTc(ss) (DeltaQTc(ss)). The maximum DeltaQTc(ss) difference between each active treatment and placebo (DeltaDeltaTc(ss)) was derived from a mixed-effect analysis of variance. Clinical laboratory tests, standard 12-lead ECGs, and vital signs were monitored at regular intervals. Spontaneously reported adverse events were recorded throughout the study. RESULTS Fifty-two healthy, nonsmoking subjects (26 men, 26 women; 37 white, 9 black, 3 Hispanic, and 3 Asian/Pacific Islander) with a mean (SD) age of 28.4 (7.5) years (range, 18-45 years) and a mean weight of 71.5 (12.6) kg (range, 49-103 kg) participated in the study. Levetiracetam did not significantly prolong the QTc(ss). The upper bound of the 1-sided 95% CI for the maximum DeltaDeltaTc(ss) was 8.0 milliseconds for levetiracetam 1000 mg and 8.1 milliseconds for levetiracetam 5000 mg, with mean estimates of 4.0 and 4.1 milliseconds, respectively; similar results were obtained for the maximum DeltaDeltaQTc(F). Moxifloxacin significantly prolonged the QTc(ss), with a lower bound of the 1-sided 95% CI for the maximum DeltaDeltaQTc(ss) of 3.7 milliseconds and a mean estimate of 7.7 milliseconds. There was no statistically significant relationship between measured DeltaQTc(ss) and the levetiracetam plasma concentration, whereas a significant linear relationship was observed between measured DeltaQTc(ss) and the moxifloxacin plasma concentration (slope estimate: 4.4 milliseconds/[microg/mL]); 95% CI, 3.2-5.7; P < 0.001). No unexpected safety concerns arose based on reported adverse events, clinical laboratory evaluations, physical examinations, vital signs, or ECG monitoring during the course of the study. CONCLUSION This randomized, placebo- and active-controlled study in healthy adult subjects found no clinically relevant changes in the QTc interval after a single levetiracetam dose of 1000 or 5000 mg.
Collapse
|
24
|
Sethuraman V, Sun Q. Impact of baseline ECG collection on the planning, analysis and interpretation of 'thorough' QT trials. Pharm Stat 2009; 8:113-24. [PMID: 18481273 DOI: 10.1002/pst.338] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The current guidelines, ICH E14, for the evaluation of non-antiarrhythmic compounds require a 'thorough' QT study (TQT) conducted during clinical development (ICH Guidance for Industry E14, 2005). Owing to the regulatory choice of margin (10 ms), the TQT studies must be conducted to rigorous standards to ensure that variability is minimized. Some of the key sources of variation can be controlled by use of randomization, crossover design, standardization of electrocardiogram (ECG) recording conditions and collection of replicate ECGs at each time point. However, one of the key factors in these studies is the baseline measurement, which if not controlled and consistent across studies could lead to significant misinterpretation. In this article, we examine three types of baseline methods widely used in the TQT studies to derive a change from baseline in QTc (time-matched, time-averaged and pre-dose-averaged baseline). We discuss the impact of the baseline values on the guidance-recommended 'largest time-matched' analyses. Using simulation we have shown the impact of these baseline approaches on the type I error and power for both crossover and parallel group designs. In this article, we show that the power of study decreases as the number of time points tested in TQT study increases. A time-matched baseline method is recommended by several authors (Drug Saf. 2005; 28(2):115-125, Health Canada guidance document: guide for the analysis and review of QT/QTc interval data, 2006) due to the existence of the circadian rhythm in QT. However, the impact of the time-matched baseline method on statistical inference and sample size should be considered carefully during the design of TQT study. The time-averaged baseline had the highest power in comparison with other baseline approaches.
Collapse
Affiliation(s)
- Venkat Sethuraman
- Biostatistics and Statistical Reporting (Oncology), Novartis Pharmaceuticals, Florham Park, NJ, USA.
| | | |
Collapse
|
25
|
Anand SP, Ghosh SK. A Bayesian Approach for Investigating the Risk of QT Prolongation. JOURNAL OF STATISTICAL THEORY AND PRACTICE 2009; 3:445-454. [DOI: 10.1080/15598608.2009.10411936] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
26
|
Collins SP, Lindsell CJ, Kontos MC, Zuber M, Kipfer P, Jost CA, Kosmicki D, Michaels AD. Bedside prediction of increased filling pressure using acoustic electrocardiography. Am J Emerg Med 2009; 27:397-408. [DOI: 10.1016/j.ajem.2008.03.014] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2008] [Revised: 03/06/2008] [Accepted: 03/06/2008] [Indexed: 02/06/2023] Open
|
27
|
Comparison of QTinno, a fully automated electrocardiographic analysis program, to semiautomated electrocardiographic analysis methods in a drug safety study in healthy subjects. J Electrocardiol 2009; 42:358-66. [PMID: 19362316 DOI: 10.1016/j.jelectrocard.2009.02.001] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2008] [Indexed: 11/20/2022]
Abstract
BACKGROUND Improved automated methods for electrocardiographic (ECG) analysis are needed, particularly for drug development purposes. OBJECTIVES This study compared a novel fully automated method for ECG analysis (QTinno; NewCardio, Santa Clara, CA) to 2 semiautomated digital methods: global measurement from the earliest QRS onset to the latest T-wave offset on representative superimposed beats (global) and tangent measurement on 3 consecutive beats in one lead (tangent). METHODS All 3 methods were used to determine uncorrected and rate-corrected QT interval duration (QT and QTcF) and related metrics in 1422 digital 12-lead ECGs from a phase 1 drug study. Global and tangent annotations were manually adjusted by the same 3 cardiologists wherever necessary. No adjustments were made in QTinno determinations. RESULTS QTinno returned QTcF change from time-matched baseline (DeltaQTcF) that differed minimally from both global and tangent methods (mean pairwise difference: 0.1 millisecond between QTinno and global, 1.1 milliseconds between QTinno and tangent). The average absolute QT and QTcF intervals by QTinno were approximately 5 milliseconds longer than global and 25 milliseconds longer than by tangent. QTinno had lower intrinsic variability for DeltaQTcF than either global or tangent (between-subject SD: QTinno 4.0 milliseconds, global 5.6 milliseconds, tangent 6.4 milliseconds; within-subject SD: QTinno 4.8 milliseconds, global 7.4 milliseconds, tangent 10.6 milliseconds). All methods were robust in detecting the largest placebo-adjusted mean time-matched DeltaQTcF (15-25 milliseconds) induced by study drug. CONCLUSIONS The methods show good agreement for drug-induced QTc prolongation. Lower intrinsic variability of DeltaQTcF by QTinno could facilitate smaller sample sizes or increase study power in thorough QTc studies.
Collapse
|
28
|
Sarapa N, Francom SF, Azzam SM, Wickremasingha PK, Tyl B. Detection of clinically significant QTc prolongation in phase I studies in healthy participants: comparison of 2 semiautomated QT measurement methods. J Clin Pharmacol 2008; 49:103-8. [PMID: 18957527 DOI: 10.1177/0091270008326717] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Affiliation(s)
- Nenad Sarapa
- Daiichi Sankyo Pharma Development, Edison, New Jersey, USA.
| | | | | | | | | |
Collapse
|
29
|
Rosillon D, Astruc B, Hulhoven R, Meeus MA, Troenaru MM, Watanabe S, Stockis A. Effect of brivaracetam on cardiac repolarisation--a thorough QT study. Curr Med Res Opin 2008; 24:2327-37. [PMID: 18601811 DOI: 10.1185/03007990802278453] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
OBJECTIVES To assess the effect on cardiac repolarisation of the investigational synaptic vesicle protein 2A (SV2A) ligand brivaracetam. RESEARCH DESIGN AND METHODS Subjects received double-blind, multiple bid doses of placebo (n = 53), brivaracetam 75 mg (n = 39) or brivaracetam 400 mg (n = 40), or open-label single-dose moxifloxacin 400 mg (positive control, n = 52). Continuous 12-lead ECG recordings were performed at baseline and after last dosing, using a Mortara Holter device. Plasma samples were obtained before and up to 12 h after last dosing for drug determination. Triplicate ECGs were extracted before each sample, and read centrally in a blinded manner. QT was corrected using a centre- and gender-specific correction (QTc(SS) ). MAIN OUTCOME MEASURES The primary endpoint was the largest time-matched mean difference of QTc(SS) change from baseline between drug and placebo (maximum DeltaDeltaQTc(SS)). The same approach was adopted using the Fridericia's correction (QTc(F)). The relationships between DeltaQTc(SS) and plasma concentration of brivaracetam and moxifloxacin were fitted to a straight line using linear least-squares regression. RESULTS Mean maximum DeltaDeltaQTc(SS) for brivaracetam 75 and 400 mg bid, and moxifloxacin 400 mg was 0.2 ms, -1.1 ms and 12.4 ms, respectively. The one-sided 95% upper limit for 75 mg and 400 mg brivaracetam was 4.3 ms and 3.0 ms, respectively; the one-sided 95% lower limit for moxifloxacin was 8.6 ms. After brivaracetam no QTc(SS) intervals > 480 ms or changes from baseline of > 60 ms were observed. DeltaQTc(SS) did not increase with plasma concentration of brivaracetam, whereas there was a statistically significant rise with increasing moxifloxacin concentrations. CONCLUSIONS The study was found to be valid in terms of assay sensitivity and the results demonstrated the absence of effects of brivaracetam on cardiac repolarisation. These results suggest that no intensive cardiac monitoring is required during the subsequent stages of brivaracetam development.
Collapse
Affiliation(s)
- D Rosillon
- Exploratory Development, UCB Pharma SA, Braine-l'Alleud, Belgium
| | | | | | | | | | | | | |
Collapse
|
30
|
Tian H, Natarajan J. Effect of baseline measurement on the change from baseline in QTc intervals. J Biopharm Stat 2008; 18:542-52. [PMID: 18470762 DOI: 10.1080/10543400802005905] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Phase I thorough QT (TQT) studies are routinely conducted by pharmaceutical companies for all new compounds to satisfy the requirements of International Conference on Harmonisation (ICH) E14 guidance on the evaluation of QTc prolongation. The primary endpoint is the change from baseline in QT interval corrected for heart rate (QTc), and the hypothesis of interest is the noninferiority of drug to placebo. Sometimes, due to the properties of the compound, it becomes necessary to use parallel group designs for TQT studies. In such situations, the effect of the baseline on the change from baseline in QTc becomes an important issue because differing baseline between the drug and placebo groups may not allow for proper estimation of the drug's effect. In this work, we evaluate the effect of baseline on the change from baseline using the placebo data from several TQT studies. Resampling techniques are used to evaluate the impact of differing baselines across groups.
Collapse
Affiliation(s)
- Hong Tian
- Johnson & Johnson Pharmaceutical Research & Development, Raritan, New Jersey 08869, USA.
| | | |
Collapse
|
31
|
Vik T, Pollard C, Sager P. Early clinical development: evaluation of drug-induced torsades de pointes risk. Pharmacol Ther 2008; 119:210-4. [PMID: 18601950 DOI: 10.1016/j.pharmthera.2008.05.006] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2008] [Accepted: 05/30/2008] [Indexed: 10/21/2022]
Abstract
Drug-induced arrhythmias or QT interval prolongation is one of the two most common reasons for drugs to be denied regulatory approval or to have warnings imposed on their clinical labelling. The assessment of torsades de pointes (TdP) risk during clinical development of a new pharmaceutical compound has been an issue of debate since the original description of drug-induced proarrhythmia. TdP risk assessment is complicated by the very low incidence (e.g., <1/100,000 patient years of exposure) of clinical events for non-antiarrhythmic agents and thus the improbable likelihood of observing even one event during clinical development. Thus surrogate methods of determining risk are necessary. A clinical approach to the issue of TdP risk assessment during drug development has been developed and implemented internationally. These efforts have markedly reduced the likelihood that drugs with unknown TdP risks will be commercialized, have resulted in fostering extensive productive pre-clinical and clinical research, and subsequent improved understanding of drug-induced proarrhythmia. Current research efforts are directed to increasing the efficiency of clinical QT assessment and the impact of pre-clinical assessment on clinical development. This article describes the clinical evaluation of TdP risk during drug development and how pre-clinical assessment can impact the early clinical development TdP risk assessment.
Collapse
Affiliation(s)
- Torbjorn Vik
- ECG Centre Cardiologist, AstraZeneca ECG Centre, Pepparedsleden 1, 431 83 Mölndal, Sweden.
| | | | | |
Collapse
|
32
|
Darpo B, Agin M, Kazierad DJ, Layton G, Muirhead G, Gray P, Jorkasky DK. Man versus machine: is there an optimal method for QT measurements in thorough QT studies? J Clin Pharmacol 2006; 46:598-612. [PMID: 16707406 DOI: 10.1177/0091270006286900] [Citation(s) in RCA: 59] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Electrocardiographic (ECG) recordings from 3 placebo-controlled thorough QT healthy volunteer studies were used to compare QT intervals obtained by manual measurement with those generated by ECG machines. The effect of the positive control was compared to placebo at each time point for data obtained from both sources. Both manual and automated techniques consistently demonstrated statistically significant prolongation of QTcF with the positive controls. The proportion of outlier values was small for both methods. The pairwise comparison between manual and automated uncorrected QT intervals demonstrated clear differences, with intervals derived from one machine on average 16 to 19 milliseconds shorter and from the other 7 milliseconds longer than the manually measured QT intervals, but these differences disappeared when analyzing QT change from baseline. Both manual and automated, commercially available QT algorithms demonstrated small statistically significant effects on the QTc interval induced by positive controls.
Collapse
Affiliation(s)
- Borje Darpo
- MSc, Clinical Statistics, Clinical R and D, Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent, CT13 9NJ, United Kingdom
| | | | | | | | | | | | | |
Collapse
|
33
|
Harris RI, Steare SE. A meta-analysis of ECG data from healthy male volunteers: diurnal and intra-subject variability, and implications for planning ECG assessments and statistical analysis in clinical pharmacology studies. Eur J Clin Pharmacol 2006; 62:893-903. [PMID: 17024488 DOI: 10.1007/s00228-006-0194-z] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2006] [Accepted: 08/01/2006] [Indexed: 10/24/2022]
Abstract
OBJECTIVE To evaluate the innate variability in key electrocardiography (ECG) parameters from clinical pharmacology studies. METHODS Meta-analysis of ECG data from seven clinical pharmacology studies in healthy male volunteers using model building and stepwise multiple regression analyses. RESULTS Data from 115 male subjects provided over 2,000 observations for all key ECG parameters from baseline (Day-1) and placebo treatment periods (Day 1). Only heart rate and uncorrected QT showed clear and marked changes over the day. QTcB had greater variability compared to QTcF. 1.4% of QTcB and 0.7% QTcF observations were >430 ms and 0.1% of QTcB and 0% of QTcF observations were >450 ms. We estimated that 8.9% of subjects would have at least one out of eight post-observation QTc value in the range 430-450 ms [assuming QTc mean 385 ms, standard deviation (SD) 20 ms] due to intrinsic variability alone. Time-matched within-subjects observations demonstrated that the SD between measurements taken 1 h apart was less than seen with a longer interval, but there was little increase in variability beyond 1 h. The probability of observing an increase in QTc of 30-60 ms in a subject was estimated as 3.0% and 21.8% for one and eight post-dose observations, respectively. The greater the number of observations used to define baseline the narrower the spread; for QTcF the SD of the baseline value was 17.1 ms for a single assessment, 13.3 ms for the mean of three assessments, and 13.2 ms for the mean of all Day-1 assessments. CONCLUSIONS The spontaneous variability in QTc measurements must be taken into account when designing studies and interpreting analyses of ECG data. The categorical analysis of QTc change of 30-60 ms is unlikely to be of any additional value to analyses of central tendency. For standard early clinical pharmacology studies, QTcF should be chosen as the primary correction method, while the mean of three measures taken in the afternoon and evening of Day-1 and pre-dose Day 1 should provide a reliable and representative baseline assessment.
Collapse
Affiliation(s)
- R I Harris
- Johnson and Johnson Pharmaceutical Research and Development, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4DP, UK
| | | |
Collapse
|
34
|
Sager PT, Nebout T, Darpo B. ICH E14: A New Regulatory Guidance on the Clinical Evaluation of QT/QTc Internal Prolongation and Proarrhythmic Potential for Non-antiarrhythmic Drugs. ACTA ACUST UNITED AC 2005. [DOI: 10.1177/009286150503900407] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
|